The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Are The Forecasted Market Size Figures For The Intermittent Claudication Market In 2026 And 2030?

The intermittent claudication market has experienced strong growth in recent years. It is anticipated to increase from $13.51 billion in 2025 to $14.31 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 5.9%. Historically, this market’s expansion can be ascribed to several factors: a rising prevalence of peripheral artery disease, an increasing aging population, a high incidence of smoking-related vascular disorders, an increase in the cardiovascular disease burden, and the expanded availability of vascular intervention procedures.

The intermittent claudication market is projected to experience robust expansion in the coming years, with its size anticipated to reach $17.98 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 5.9%. This significant growth during the forecast period can be attributed to heightened awareness regarding peripheral artery disease symptoms, an increasing demand for minimally invasive vascular treatments, ongoing advancements in pharmacological therapies, the rising adoption of home-based disease management strategies, and improved screening and diagnostic programs. Prominent trends expected in this period include a greater emphasis on the early diagnosis of peripheral artery disease, an increase in the use of combination drug therapies, a growing preference for minimally invasive revascularization procedures, the expansion of supervised exercise therapy programs, and enhanced patient awareness and disease management practices.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=22021&type=smp

Which Growth Factors Are Strengthening The Intermittent Claudication Market Landscape?

The rising prevalence of peripheral artery disease (PAD) is anticipated to boost the expansion of the intermittent claudication market in the coming years. Peripheral artery disease is a circulatory condition where narrowed arteries decrease blood flow to the limbs, causing pain, numbness, and other complications. The increase in PAD cases is linked to factors such as an aging population, diabetes, smoking, hypertension, obesity, and sedentary lifestyles. Peripheral artery disease (PAD) leads to intermittent claudication by reducing blood flow to leg muscles during exercise, causing pain and cramping due to a lack of oxygen. For instance, in June 2023, according to the American Heart Association Journals, a US-based peer-reviewed open-access scientific journal, peripheral artery disease (PAD) affects 7-12 million in the U.S. and 200 million globally. Consequently, the growing number of peripheral artery disease (PAD) cases is stimulating the growth of the intermittent claudication market.

How Is The Intermittent Claudication Market Distributed Across Key Segments?

The intermittent claudication market covered in this report is segmented –

1) By Type: Medication Therapies, Revascularization

2) By Route Of Administration: Parenteral Route, Oral Route, Other Routes Of Administration

3) By Application: Hospitals, Clinics, Home Healthcare, Other Applications

4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

Subsegments:

1) By Medication Therapies: Antiplatelet Agents, Vasodilators, Phosphodiesterase Inhibitors, Cilostazol, Pentoxifylline

2) By Revascularization: Angioplasty, Stenting, Bypass Surgery, Endarterectomy

Which Trends Are Supporting The Evolution Of The Intermittent Claudication Market?

Major companies operating within the Intermittent Claudication market are increasingly focusing on the integration of minimally invasive endovascular innovations, such as percutaneous bypass systems, to elevate treatment efficacy, procedural success, and patient outcomes. Percutaneous bypass systems are sophisticated vascular technologies designed to create an endovascular bypass pathway using specialized stent grafts and catheters, offering capabilities like restoring blood flow across extensive arterial blockages, diminishing reliance on open surgical bypass, and promoting faster patient recovery. For example, in June 2023, Endologix LLC, a US-based medical device company dedicated to vascular disease therapies, secured FDA approval for its DETOUR System, which is a minimally invasive percutaneous bypass solution developed to treat long, complex superficial femoropopliteal lesions in patients diagnosed with peripheral artery disease (PAD). This system incorporates the TORUS stent graft platform, an innovative endovascular bypass technique, and possesses the ability to manage long-segment occlusions, facilitating effective treatment for challenging femoropopliteal blockages. The DETOUR System significantly improves blood flow restoration, reduces procedural morbidity, and expands the range of treatment options for patients experiencing symptomatic PAD and Intermittent Claudication.

Who Are The Businesses Driving Activity In The Intermittent Claudication Market?

Major companies operating in the intermittent claudication market are Pfizer Inc., Bristol Myers Squibb Company, AstraZeneca PLC, Novartis AG, Teva Pharmaceutical, Otsuka Pharmaceutical Co. Ltd., Sanofi S.A., Bayer AG, Hikma Pharmaceuticals PLC, Dr. Reddy’s Laboratories, Alkem Laboratories, Aastrid Life Sciences Pvt. Ltd., Manus Aktteva Biopharma LLP, Enomark Pharma.

Access The Complete Intermittent Claudication Market Report:

https://www.thebusinessresearchcompany.com/report/intermittent-claudication-global-market-report

Which Region Contributes The Most To The Intermittent Claudication Market?

North America was the largest region in the intermittent claudication market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the intermittent claudication market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Intermittent Claudication Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/customise?id=22021&type=smp

Browse Through More Reports Similar to the Global Intermittent Claudication Market 2026, By The Business Research Company

Biomaterial Wound Dressing Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/biomaterial-wound-dressing-global-market-report

Wound Contact Layer Dressing Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/wound-contact-layer-dressing-global-market-report

Surgical Dressing Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/surgical-dressing-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model